Risks of hypertension associated with cyclosporine, nonsteroidal anti-inflammatory drugs, and systemic glucocorticoids in patients with psoriasis: A nationwide population-based nested case-control study in Taiwan

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 2, 2016, Pages 133-140

  Lee, Meng Sui ^a,b   Chang, Chia Hsuin ^c,d,e   Lin, Ruey Yi ^a   Lai, Mei Shu ^c  

^a TAIPEI CITY HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL TAIWAN UNIVERSITY   (Taiwan)

Author keywords

Cyclosporine; Hypertension; Nonsteroidal anti inflammatory drugs; Pharmacoepidemiology; Psoriasis; Systemic glucocorticoids

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; DERMATOLOGICAL AGENT;

ADULT; ARTICLE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; COHORT ANALYSIS; DRUG EXPOSURE; FEMALE; HUMAN; HYPERTENSION; MALE; MORBIDITY; POPULATION RESEARCH; PRIORITY JOURNAL; PSORIASIS; PSORIATIC ARTHRITIS; SYSTEMIC THERAPY; TAIWAN; AGED; CASE CONTROL STUDY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; HEALTH SURVEY; LONGITUDINAL STUDY; MIDDLE AGED; PROCEDURES; RISK FACTOR;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASE-CONTROL STUDIES; CYCLOSPORINE; DERMATOLOGIC AGENTS; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; HYPERTENSION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PSORIASIS; RISK FACTORS; TAIWAN;

EID: 84955628436     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3890     Document Type: Article

References (35)

1. Raychaudhuri SP, Farber EM. The prevalence of psoriasis in the world. J Eur Acad Dermatol Venereol 2001; 15: 16-17.
2. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778-783.
3. Gelfand JM, Shin DB, Neimann AL, et al. The risk of lymphoma in patients with psoriasis. J Invest Dermatol 2006; 126: 2194-2201.
4. Lee MS, Lin RY, Lai MS. Increased risk of diabetes mellitus in relation to the severity of psoriasis, concomitant medication, and comorbidity: a nationwide population-based cohort study. J Am Acad Dermatol 2014; 70: 691-698.
5. Abuabara K, Azfar RS, Shin DB, et al. Cause-specific mortality in patients with severe psoriasis: a population-based cohort study in the U.K. Br J Dermatol 2010; 163: 586-592.
6. Coumbe AG, Pritzker MR, Duprez DA. Cardiovascular risk and psoriasis: beyond the traditional risk factors. Am J Med 2014; 127: 12-18.
7. Gladman DD. Mortality in psoriatic arthritis. Clin Exp Rheumatol 2008; 26: S62-65.
8. Neimann AL, Shin DB, Wang X, et al. Prevalence of cardiovascular risk factors in patients with psoriasis. J Am Acad Dermatol 2006; 55: 829-835.
9. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-952.
10. Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens 2013; 31: 433-442.
11. Qureshi AA, Choi HK, Setty AR, et al. Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol 2009; 145: 379-382.
12. Cohen AD, Gilutz H, Henkin Y, et al. Psoriasis and the metabolic syndrome. Acta Derm Venereol 2007; 87: 506-509.
13. Cohen AD, Weitzman D, Dreiher J. Psoriasis and hypertension: a case-control study. Acta Derm Venereol 2010; 90: 23-26.
14. Rosmarin DM, Lebwohl M, Elewski BE, et al. Cyclosporine and psoriasis: 2008 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2010; 62: 838-853.
15. Mahajan VK, Sharma AL, Chauhan PS, et al. Early treatment with addition of low dose prednisolone to methotrexate improves therapeutic outcome in severe psoriatic arthritis. Indian J Dermatol 2013; 58: 240.
16. Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev 2010; (1): CD007893.
17. Gisondi P, Cazzaniga S, Chimenti S, et al. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. J Eur Acad Dermatol Venereol 2013; 27: e30-41.
18. Johnson AG. NSAIDs and increased blood pressure. What is the clinical significance? Drug Saf 1997; 17: 277-289.
19. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. Rheumatology (Oxford) 2008; 47: 72-75.
20. The Longitudinal Health Insurance Database. The longitudinal health insurance database. http://w3.nhri.org.tw/nhird/en/Data_Subsets.html#S3 (accessed 31 October 2014).
21. Chen Y-C, Yeh H-Y, Wu J-C, et al. Taiwan's National Health Insurance Research Database: administrative health care database as study object in bibliometrics. Scientometrics 2011; 86: 365-380.
22. Richardson DB. An incidence density sampling program for nested case-control analyses. Occup Environ Med 2004; 61: e59.
23. Who collaborating centre for drug statistics methodology. Defined daily dose: definition and general considerations. http://www.whocc.no/ddd/definition_and_general_considera/ (accessed 31 October 2014).
24. Delgado-Rodriguez M, Llorca J. Bias J Epidemiol Community Health 2004; 58: 635-641.
25. Grossman E, Messerli FH. Secondary hypertension: interfering substances. J Clin Hypertens (Greenwich) 2008; 10: 556-566.
26. Grossman E, Messerli FH. Drug-induced hypertension: an unappreciated cause of secondary hypertension. Am J Med 2012; 125: 14-22.
27. Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-1741.
28. Ferrandiz C, Pujol RM, Garcia-Patos V, et al. Psoriasis of early and late onset: a clinical and epidemiologic study from Spain. J Am Acad Dermatol 2002; 46: 867-873.
29. Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-456.
30. Langley RG, Krueger GG, Griffiths CE. Psoriasis: epidemiology, clinical features, and quality of life. Ann Rheum Dis 2005; 64(Suppl 2): ii18-23.
31. Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res 2011; 46: 399-424.
32. Song JW, Chung KC. Observational studies: cohort and case-control studies. Plast Reconstr Surg 2010; 126: 2234-2242.
33. Essebag V, Genest J, Jr, Suissa S, et al. The nested case-control study in cardiology. Am Heart J 2003; 146: 581-590.
34. Uddin MJ, Groenwold RH, de Boer A, et al. Performance of instrumental variable methods in cohort and nested case-control studies: a simulation study. Pharmacoepidemiol Drug Saf 2014; 23: 165-177.
35. Rothman KJ, Greenland S, Lash TL. Modern Epidemiology. Wolters Kluwer Health/Lippincott Williams & Wilkins: Philadelphia, PA, 2008; 177.